Oral ART

DRUG2 trials

Sponsors

University of California, San Francisco, ViiV Healthcare

Conditions

HIV Infections

Phase 3

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Active, not recruitingNCT06694805

ViiV HealthcareHIV Infections

Start: 2024-12-02End: 2028-06-08Updated: 2026-07-29

Unknown Phase

Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home

Enrolling by invitationNCT06488846

University of California, San FranciscoHIV Infections

Start: 2026-02-16End: 2027-09-29Target: 1000Updated: 2026-05-01

Related Papers

Innovative administration of long-acting injectables for HIV treatment enhancement at home (INVITE-HOME): implementation science study protocol

BMJ Open2025-08-01